One anastomosis gastric bypass (OAGB): Scoping review

This release archives the complete reproducibility package for the peer-reviewed scoping review: Ortíz-Gómez JE, González-Barajas AI, Guevara-Díaz JA, Mancilla-Galindo J, Kammar-García A, Guerrero-Gutierrez MA. One anastomosis gastric bypass (OAGB): a scoping review. BMC Surgery. 2025;25(1):471. https://doi.org/10.1186/s12893-025-03215-x The article is Open Access under a CC BY 4.0 license. This archive (code, data, and documentation) is released under the MIT License. About the study This scoping review synthesises evidence from 67 studies (out of 3,791 records screened) on One Anastomosis Gastric Bypass (OAGB), also known as mini-gastric bypass (MGB), across four clinical domains: percentage excess weight loss (%EWL), remission of metabolic and cardiovascular conditions, postoperative complications, and incidence of gastroesophageal reflux disease (GERD). Key findings: OAGB showed higher or comparable %EWL versus Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and SADI-S, particularly in short- and mid-term follow-up. Type 2 diabetes remission ranged from 76.8% to 100%, with meaningful improvements in hypertension, dyslipidemia, and obstructive sleep apnea. GERD and bile reflux remain the main long-term concerns; reported de novo GERD rates ranged from 6% to 57%, and the YOMEGA randomised trial reported 41% in OAGB versus 18% in RYGB. Longer biliopancreatic limbs enhanced weight loss but increased nutritional risk. Substantial heterogeneity in how outcomes (especially %EWL and "ideal weight") were defined across studies limits meta-analytic comparability and motivates a call for standardised reporting. Methodologically, the review followed PRISMA-ScR, used the ASReview active-learning tool for AI-assisted record screening, and the ASySD tool for deduplication. Contents of this archive R/ — Quarto (.qmd) source files documenting the literature search, deduplication, and ASReview record handling. asreview/ — exported ASReview project files, importable into ASReview LAB to inspect screening decisions and reproduce the active-learning workflow. docs/reports/ — rendered PDF and DOCX reports of each analysis step. docs/rob/ — full Cochrane RoB 2.0 assessment for the included randomised controlled trials. data/ — raw and processed search outputs. results/ — figures and tables generated from the analysis. Reuse scenarios Re-running or extending the literature search with updated dates. Importing the ASReview project to audit screening decisions or to use as prior knowledge for related evidence syntheses on bariatric surgery. Adapting the search strategy or the ASReview workflow as a template for other scoping or systematic reviews. Citing the methodological approach (PRISMA-ScR + ASReview active-learning screening + Cochrane RoB 2.0) in the methods sections of future evidence-synthesis work. How to cite If you reuse any part of this archive, please cite both the published article (preferred) and this Zenodo record: Article: Ortíz-Gómez JE, González-Barajas AI, Guevara-Díaz JA, Mancilla-Galindo J, Kammar-García A, Guerrero-Gutierrez MA. One anastomosis gastric bypass (OAGB): a scoping review. BMC Surgery. 2025;25(1):471. doi:10.1186/s12893-025-03215-x Related resources GitHub repository (live version): https://github.com/javimangal/OAGB-review Published article (Open Access): https://doi.org/10.1186/s12893-025-03215-x Software and reproducibility Analyses were conducted in R version 4.5.0 with RStudio 2025.05.0. Screening used ASReview LAB v.2.0.2. Deduplication used ASySD. Risk-of-bias assessment used the Cochrane RoB 2.0 Excel implementation. Keywords bariatric surgery; metabolic and bariatric surgery; one anastomosis gastric bypass; OAGB; mini-gastric bypass; MGB; Roux-en-Y gastric bypass; RYGB; sleeve gastrectomy; SADI-S; obesity; obesity management; type 2 diabetes remission; gastroesophageal reflux disease; GERD; bile reflux; biliopancreatic limb; nutritional deficiencies; scoping review; evidence synthesis; PRISMA-ScR; ASReview; active learning; AI-assisted screening; Cochrane RoB 2.0